Sort   by:  
 Page size 
GenomicsTargeting transcriptional dependencies in cancer using a covalent CDK7 inhibitor (ChIP-Seq)
Cyclin-dependent kinase 7 (CDK7) plays a critical role in the general regulation of RNA polymerase II-mediated transcription. However, the absence of selective CDK7 inhibitors has hindered the ability to investigate the consequences of acute and prolonged inhibition of CDK7 under normal and patholo...
ORGANISM(S): Homo sapiens 
2013-12-23 | E-GEOD-50622 | biostudies-arrayexpress
ProteomicsEffect of CDK7 inhibitor on protein expression alterations in cultured secondary AML HEL92.1.7 cells
HEL92.1.7 cells in exponential growth phase were treated with 100 nM of SY-5609 for 24 hours to determine the global protein expression alterations that correlate with the cell cycle, growth inhibitory and lethal effects of treatment with a CDK7 inhibitor in secondary AML cells.
ORGANISM(S): Homo sapiens (Human) 
2025-04-28 | PXD053572 | Pride
Secondary aml Cdk7 inhibitor C-myc 
TranscriptomicsTargeting transcriptional dependencies in cancer using a covalent CDK7 inhibitor (expression)
Cyclin-dependent kinase 7 (CDK7) plays a critical role in the general regulation of RNA polymerase II-mediated transcription. However, the absence of selective CDK7 inhibitors has hindered the ability to investigate the consequences of acute and prolonged inhibition of CDK7 under normal and patholo...
ORGANISM(S): Homo sapiens 
2014-06-22 | E-GEOD-50624 | biostudies-arrayexpress
TranscriptomicsCDK7-dependent Transcriptional Addiction in Triple-Negative Breast Cancer (Microarray)
Triple-negative breast cancer (TNBC) is a highly aggressive form of breast cancer that exhibits extremely high levels of genetic complexity and yet a relatively uniform transcriptional program. We postulate that TNBC might be highly dependent on uninterrupted transcription of a key set of genes with...
ORGANISM(S): Homo sapiens 
2015-09-24 | E-GEOD-69106 | biostudies-arrayexpress
ProteomicsEffect of CDK7 inhibitor, FHD-286, SNDX-50469, or Tasquinimod on protein expression alterations in patient-derived secondary AML or de novo MLL1-rearranged AML cells
Patient-derived secondary AML cells were treated with 100 nM of SY-5609 for 24 hours, 100 nM of FHD-286 for 48 hours, or 20 µM of Tasquinimod for 48 hours to determine the global protein expression alterations that correlate with the cell cycle, growth inhibitory and lethal effects of treatment with...
ORGANISM(S): Homo sapiens (Human) 
2025-04-28 | PXD053548 | Pride
Secondary aml Sndx-50469 Tasquinimod Cdk7 inhibitor Fhd-286 
GenomicsCDK7-dependent Transcriptional Addition in Basal-like Breast Cancer
Basal-like breast cancer (BBC) is a highly aggressive form of breast cancer that exhibits extremely high levels of genetic complexity and yet a relatively uniform transcriptional program. We postulate that BBC might be highly dependent on uninterrupted transcription of a key set of genes within this...
ORGANISM(S): Homo sapiens 
2015-01-23 | E-GEOD-65201 | biostudies-arrayexpress
GenomicsA novel covalent inhibitor of CDK7 synergizes with Venetoclax in acute myeloid leukemia
A novel covalent inhibitor of CDK7 synergizes with Venetoclax in acute myeloid leukemia
PRJNA967615 | ENA
GenomicsDevelopment of a selective CDK7 covalent inhibitor reveals predominant cell cycle phenotype
Development of a selective CDK7 covalent inhibitor reveals predominant cell cycle phenotype
PRJNA512643 | ENA
GenomicsTranscriptomic profiling of mouse lung tumor cells in response to CDK7 inhibitor treatment
Transcriptomic profiling of mouse lung tumor cells in response to CDK7 inhibitor treatment
PRJNA566130 | ENA
GenomicsEffect of CDK7 inhibitor on MYCN-amplified retinoblastoma
Effect of CDK7 inhibitor on MYCN-amplified retinoblastoma
PRJNA989247 | ENA
Sort   by:  
 Page size